Editorial comment

摘要

Editorial Comment: The authors have developed a semisynthetic method for the production of bispecific antibody-like therapeutics consisting of a small molecule targeting moiety conjugated to an antibody. A highly selective prostate specific membrane antigen binding ligand was site specifically conjugated to a mutant a cluster of differentiation 3 (aCD3) Fab containing an unnatural amino acid with orthogonal chemical reactivity. The optimized conjugate showed potent in vitro activity, good serum half-life and potent in vivo activity in prostate cancer xenograft mouse models. This simple (1-step conjugation and purification) and high yielding (greater than 90%) semisynthetic approach also is suitable for combinatorial synthesis of diverse bispecific antibbdies to screen quickly for optimal combinations of the target and effector cell binding components.